SQI Diagnostics Inc V.SQD.H

Four Pending FDA/EUA Submission/Approvals over weeks ahead

[FactFinder1994]

1) RALI-Dx 

2) RALI-fast 

3) COVID At-Home Antibody Test 

4) TORdx Lung 

 

Each of these products provides a revenue opportunity of greater than $250M annually, with an FDA stamp.  

 

SQI could go from south of a hundred million dollar market cap to north of a billion dollar market cap in a relatively short period of time.

 

If not for the under the radar strategy, SQI would already be valued at above a dollar per share.

 

STAY TUNED     

[FactFinder1994]

Each FDA EUA/approval, is worth at least $200M USD ($250M CAD) in immediate additional market cap, (before you even generate a dollar of related revenue).   That equates to an incremental 50 cents/share (CAD) on a fully diluted basis per approval.   Get all four FDA approvals, commence sales, and your approaching $3/share by the end of Fiscal 2021.  (not bad, at 10 times current